reference/36205789

Predicate	Object
contentType	Case Reports\|Journal Article
endingPage	291
issn	0959-4973
issueIdentifier	3
pageRange	288-291
startingPage	288
bibliographicCitation	Wang X, Yang K, Yang Y, Wang X, Yuan K. Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/CTLA-4 Bi-specific antibody): a case report. Anticancer Drugs. 2024 Mar 01;35(3):288–91. doi: 10.1097/cad.0000000000001557. PMID: 37982205.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83cacfd2c225510b07ea1dc7c1e85ff1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a44edd0d2fcfb179993ecc73698124c5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47ce853b184279c3023f1c9be592790a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2be4a4e252d3020e10f14539bafe5811
date	2023-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/37982205 https://doi.org/10.1097/cad.0000000000001557
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1267 https://portal.issn.org/resource/ISSN/0959-4973
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/CTLA-4 Bi-specific antibody): a case report
discusses	http://id.nlm.nih.gov/mesh/M0556121 http://id.nlm.nih.gov/mesh/M0555800

Total number of triples: 23.